Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Conventional treatment for reducing pain is not always successful in patients with chronic orofacial myalgia.

Objective: The objective of this study was to investigate the pain-reducing efficacy of two botulinum toxin A injections in patients with chronic orofacial myalgia who had already received conservative treatment.

Methods: The patients included were 18 years or older and diagnosed with myalgia according to the Diagnostic Criteria for Temporomandibular Disorders. Their pain had persisted for more than six months in spite of previous conservative treatment. The design was a randomised, double-blind, placebo-controlled, multicenter, parallel group study. Participants received two injections of botulinum toxin A or saline at an interval of three months. Follow-up visits were conducted at one, three, four, six and nine months after the first injection.

Results: Seventy-two patients were enrolled and sixty-nine completed the study. Between baseline and all follow-up visits, there was a significant decrease in VAS pain intensity for both groups, but the difference between groups was not significant.

Conclusion: The use of botulinum toxin A in managing chronic orofacial myalgia did not offer any additional pain relief compared with saline at any of the follow-up occasions.

Download full-text PDF

Source
http://dx.doi.org/10.1111/joor.70032DOI Listing

Publication Analysis

Top Keywords

botulinum toxin
16
chronic orofacial
16
patients chronic
12
orofacial myalgia
12
toxin injections
8
injections patients
8
randomised double-blind
8
three months
8
follow-up visits
8
patients
5

Similar Publications

Background: Keloids are fibroproliferative disorders characterized by excessive scarring, functional impairment, and aesthetic concerns. Despite the availability of various treatments, recurrence rates remain high, highlighting the need for alternative therapies with favorable safety profiles. Botulinum toxin A (BTX-A) has emerged as a potential option for keloid treatment; however, its therapeutic role is still not fully elucidated.

View Article and Find Full Text PDF

Perineural botulinum toxin in the management of post-traumatic headache: a case report.

Rev Esp Anestesiol Reanim (Engl Ed)

September 2025

Physical Medicine and Rehabilitation. Universidad del Valle, Cali, Colombia; Interventional Pain Management, Fundalivio, Cali, Colombia.

Post traumatic headache is a common condition that can be managed with pharmacologic interventions or analgesic procedures; however, most evidence is derived from patients with mild trauma, leaving a large gap with regard to patients with moderate or severe trauma who present complex pain. Botulinum toxin plays an increasingly important role in pain management. This neurotoxin acts on different receptors, ranging from TRPV1 (transient receptor potential vanilloid type 1) to CGRP (calcitonin gene-related peptide).

View Article and Find Full Text PDF

Objective: To investigate the potential relationship between retrograde cricopharyngeal dysfunction (R-CPD) and laryngopharyngeal reflux disease (LPRD) at baseline and whether cricopharyngeal sphincter paralysis botulinum toxin injection (BTI) is associated with an increase of LPRD symptoms in treated R-CPD patients.

Methods: Patients with clinical diagnosis of R-CPD were prospectively recruited from two European hospitals. Controls included individuals unable to burp without troublesome symptoms (CT1) and healthy subjects able to burp (CT2).

View Article and Find Full Text PDF

Introduction: Botulinum toxin type A (BoNT/A) is commonly used for both medical and aesthetic purposes. However, approximately 3% of long-term recipients develop resistance, potentially due to antibody formation. Injection technique may influence immunogenicity, yet comparative data remain limited.

View Article and Find Full Text PDF